1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA Implementing Hybrid Work Policy In January

 
• By Derrick Gingery

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

FDA hybrid work
Individual duties will help determine whether on-site, telework and remote working options will be available for FDA employees. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The US Food and Drug Administration will not require all employees to resume their daily treks to the office going forward, choosing a “hybrid workplace model” that will go into effect in January 2023.

Commissioner Robert Califf made the change after the agency completed a six-month pilot exploring workplace flexibilities. The FDA said the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

Business Background Of New CDER Director George Tidmarsh

 
• By Bridget Silverman

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By Sue Sutter

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."

Will Tidmarsh’s Industry Experience Translate As US FDA’s Chief Drug Regulator?

 
• By Sarah Karlin-Smith and Derrick Gingery

The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.

More from Agency Leadership